Ken Griffin Vanda Pharmaceuticals Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$3.47 - $4.61 $60,031 - $79,753	17,300 Added 95.05%	35,500 $145,000
Q4 2023 Feb 14, 2024	BUY	$3.38 - $4.58 $46,306 - $62,746	13,700 Added 304.44%	18,200 $76,000
Q3 2023 Nov 14, 2023	BUY	$4.28 - $6.57 $7,276 - $11,169	1,700 Added 60.71%	4,500 $19,000
Q2 2023 Aug 14, 2023	BUY	$5.9 - $6.95 $6,490 - $7,645	1,100 Added 64.71%	2,800 $18,000
Q1 2023 May 15, 2023	SELL	$6.18 - $7.99 $27,192 - $35,156	-4,400 Reduced 72.13%	1,700 $11,000

Q4 2022 Feb 14, 2023	BUY	$6.87 - $10.96 $41,907 - $66,856	6,100 New	6,100 $45,000

147

49.6M

49.1K

107K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $320M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.